[
  {
    "question": "Known case of epilepsy female on lamotrigine and wanted to started on OCB; what you will tell her?",
    "option_a": "double lamotrigine dose.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Lamotrigine is metabolized primarily via glucuronidation, and estrogen-containing oral contraceptive pills (OCPs) induce hepatic UGT enzymes. This induction leads to increased clearance of lamotrigine. Estrogen in OCPs accelerates the activity of uridine glucuronyl transferases (UGTs) which enhances the glucuronidation of lamotrigine. The increased metabolism results in lower plasma levels of lamotrigine, which can compromise seizure control in patients with epilepsy. A female patient with epilepsy maintained on lamotrigine who starts OCPs is at risk for breakthrough seizures due to a decrease in the effective concentration of her anticonvulsant. Recognizing this interaction is critical for maintaining seizure control. Monitoring serum lamotrigine levels before and after initiation of OCPs is advised. Differential considerations include noncompliance or other drug interactions that might similarly reduce lamotrigine levels. A careful review of her medication history and lab monitoring can differentiate these causes. First-line management involves counseling the patient about the potential for reduced lamotrigine levels and the likely need to increase her lamotrigine dose\u2014often empirically around a doubling of the dose\u2014while basing adjustments on therapeutic drug monitoring. In pregnancy and lactation, similar considerations apply as pregnancy itself increases lamotrigine clearance, and dose adjustments should be individualized and closely monitored. Option A (\u2018double lamotrigine dose\u2019) is correct as it directly addresses the anticipated increase in lamotrigine clearance due to the initiation of OCPs. Other options (not provided) would likely not address the underlying drug interaction adequately. 1. Estrogen-containing OCPs can decrease lamotrigine levels by up to 60-100%, risking breakthrough seizures. 2. Always consider drug interactions when seizure control deteriorates. 3. Use therapeutic drug monitoring to individualize dose adjustments. Recent pharmacokinetic studies confirm that estrogen components in OCPs significantly reduce lamotrigine levels, supporting dose uptitration based on serum level monitoring. Updated guidelines emphasize individualized dose management rather than a one\u2010size\u2010fits\u2010all approach.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "23 y.o male pt on lamotragine 200 BID had tonic clonic seizure not fully controlled and came to the clinic, what you will add for her? All other neurology examination intact",
    "option_a": "(Keppra/levetiracetam) is correct. Option 2 (Depakin/valproate), while effective, carries a higher risk of side effects including hepatotoxicity and weight gain. Option 3 (Topamax/topiramate) is limited by cognitive side effects. Option 4 (None) would not address the ongoing seizure activity.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "When seizures persist despite current monotherapy, adding a second antiepileptic with a complementary mechanism of action is a standard approach for refractory epilepsies. Lamotrigine works by inhibiting voltage-sensitive sodium channels, thereby stabilizing neuronal membranes. Levetiracetam (Keppra) works by binding to synaptic vesicle protein SV2A and modulates neurotransmitter release, which makes it effective as an adjunct in reducing seizure frequency when added to lamotrigine. A 23-year-old male who continues to experience generalized tonic-clonic (TC) seizures despite being on lamotrigine would benefit from adjunctive therapy. The addition of levetiracetam can help reduce seizure frequency given its favorable profile and minimal drug interactions. Before modifying therapy, ensure that the patient's lamotrigine levels are within the therapeutic range and confirm adherence. Differential diagnoses may include subtherapeutic dosing, pharmacokinetic issues, or misdiagnosed seizure type. Once these are ruled out, adjunctive therapy is warranted. First-line management involves adding levetiracetam as an adjunct due to its proven efficacy, safety, and minimal interaction profile with lamotrigine. In male patients (and similarly in females), levetiracetam is widely regarded as a suitable add-on. For pregnant or lactating patients, levetiracetam is also favored because of its lower teratogenic risk and relatively stable pharmacokinetics, though dose adjustments may be required based on serum level monitoring. Option A (Keppra/levetiracetam) is correct. Option 2 (Depakin/valproate), while effective, carries a higher risk of side effects including hepatotoxicity and weight gain. Option 3 (Topamax/topiramate) is limited by cognitive side effects. Option 4 (None) would not address the ongoing seizure activity. 1. Levetiracetam is an excellent adjunct due to its minimal drug-drug interactions. 2. Always rule out noncompliance or inadequate dosing before modifying therapy. 3. Monitor for potential side effects even with well-tolerated adjuncts. Recent clinical guidelines and studies support the use of levetiracetam as an adjunctive therapy for generalized tonic-clonic seizures, highlighting its favorable safety profile and efficacy in combination with other AEDs like lamotrigine.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "HIV Patient came with seizure what is the culprit medication",
    "option_a": "(Efavirenz) is correct because it is the most well",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Certain antiretroviral therapies used in HIV management are known to have CNS effects. Recognizing drug-induced neurotoxicity is key in managing seizures in HIV patients. Efavirenz, an NNRTI used in HIV treatment, has well-documented neuropsychiatric side effects including dizziness, vivid dreams, mood changes, and seizures. It exerts these effects through modulation of neurotransmitter pathways and may cause mitochondrial toxicity, lowering the seizure threshold. In an HIV patient who develops seizures, the temporal association with the initiation or use of efavirenz should raise suspicion for drug-induced neurotoxicity. Other ART medications are less likely to induce seizures, supporting efavirenz as the responsible agent. A detailed medication history is critical. Differential diagnoses include opportunistic CNS infections (such as toxoplasmosis or cryptococcal meningitis), metabolic derangements, or other medications. The strong temporal and pharmacovigilance data linking efavirenz to seizures helps differentiate it from other causes. Management involves reassessing the antiretroviral regimen. If efavirenz is implicated, it may be replaced with an alternative agent that does not lower the seizure threshold. In pregnant patients, efavirenz is generally avoided in the first trimester due to teratogenic risks, and similar caution is exercised in lactating mothers. Option A (Efavirenz) is correct because it is the most well-documented ART associated with neuropsychiatric and seizure-provoking side effects. Other options (e.g., nevirapine, zidovudine, lamivudine) have minimal associations with seizures. 1. Always review the patient\u2019s full medication list when new neurologic symptoms arise. 2. Efavirenz is notorious for CNS side effects, including seizures. 3. Consider drug-induced etiologies in HIV patients with new onset of neurological symptoms. Recent studies and pharmacovigilance reports have reinforced the association between efavirenz and CNS toxicity. Updated HIV treatment guidelines highlight the risk of neuropsychiatric effects and recommend monitoring or switching therapy when significant symptoms, including seizures, occur.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "25 years old pregnant lady came and she need counciling regard AED during pregnancy",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Pregnant women with epilepsy require careful management to balance seizure control with minimizing fetal exposure to teratogenic drugs. Selecting an antiepileptic drug (AED) with lower teratogenic potential is essential. AEDs vary in their teratogenic risk profiles. While medications like valproate and, to a lesser degree, phenytoin and carbamazepine present increased risks of congenital malformations, levetiracetam (Keppra) is associated with a much lower risk. The pharmacokinetics of levetiracetam also remain relatively stable during pregnancy. In a 25\u2010year\u2010old pregnant woman needing counseling on AED use during pregnancy, advising a switch to or use of a safer AED is paramount to reduce the risk of fetal malformations while still controlling maternal seizures. A careful review of the patient\u2019s current AED regimen, seizure control status, and the comparative teratogenic risks of available drugs is needed. Differential diagnosis in counseling includes assessing the safety of continuing current therapy (e.g., lamotrigine with dose adjustment) versus switching to an agent with lower teratogenicity like levetiracetam. First-line management for pregnant or childbearing-age women with epilepsy is to use AEDs that have the lowest risk of congenital malformations. Levetiracetam is widely regarded as one of the safest options. If a patient is already on lamotrigine, careful monitoring and dose adjustments are necessary due to increased clearance during pregnancy. Valproate and drugs with higher teratogenicity (such as carbamazepine being incorrectly labeled as the 'most teratogenic') should be avoided. In lactation, levetiracetam is also preferred because of minimal drug transfer and low risk to the infant. Option 1 (\u2018Increase the dose of lamotrigine in 1st and 2nd trimester\u2019) is partially correct as lamotrigine clearance does increase; however, it does not address overall fetal safety risks compared to other AEDs. Option 2 (\u2018Keppra is the safest drug during pregnancy\u2019) is correct, supported by evidence favoring levetiracetam\u2019s teratogenic profile and stable pharmacokinetics. Option 3 (\u2018Carbamazepine is the most teratogenic during pregnancy\u2019) is incorrect; carbamazepine is not the most teratogenic (valproate typically poses the highest risk). Option 4 (\u2018Phenytoin and depakin increase metabolism during pregnancy\u2019) is incorrect as a misinterpretation of pharmacokinetic changes during pregnancy. 1. Levetiracetam is among the AEDs with the lowest teratogenic risk and is preferred in pregnancy. 2. Lamotrigine\u2019s dosing may require adjustment during pregnancy due to increased metabolism. 3. Avoid high-risk AEDs such as valproate in women of childbearing potential. Recent cohort studies and guideline updates from organizations such as the American Academy of Neurology support the preferential use of levetiracetam in pregnant women with epilepsy. These guidelines emphasize individualized treatment plans, therapeutic drug monitoring, and consideration of both maternal seizure control and fetal safety.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "pt with MTL on 2 AED came to the clinic. What is the reason of her breakthrough seizure?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Breakthrough seizures in patients with mesial temporal lobe (MTL) epilepsy can occur despite treatment with antiepileptic drugs (AEDs), and one of the most common reasons is non-adherence to the medication regimen. Even when a patient is on two AEDs, missing doses directly lowers the AED serum concentration, decreasing seizure control. Antiepileptic medications work by raising the seizure threshold. When patients do not take their medications as prescribed, the levels fall below the therapeutic range. This subtherapeutic state predisposes neurons to hyperexcitability. Studies have repeatedly shown that non-adherence is a leading, and modifiable, cause of breakthrough seizures. In the clinic, a patient presenting with breakthrough seizures should prompt a review of medication adherence, possible side effects causing unintentional non-compliance, and even potential drug\u2013drug interactions. In patients with MTL epilepsy who have been stable, a single missed dose can precipitate a seizure. Assessment includes reviewing patient history, pill counts, and serum drug levels if available. Differential diagnoses include pharmacokinetic issues, drug interactions, new metabolic or structural changes, or even pseudoresistance due to non-adherence. A careful medication history is key. First-line management emphasizes counseling on adherence, possibly supplementing with drug-level monitoring. In patients with confirmed non-adherence, addressing barriers (such as side effects, complex regimens, or misunderstanding) is essential. When counseling pregnant or lactating patients, clinicians must consider that physiological changes may alter drug pharmacokinetics, so even stricter adherence and monitoring are recommended. Option A \u2013 non-adherence \u2013 is correct as it identifies the most common and modifiable cause of breakthrough seizures. Other options (such as attributing the seizure to the baseline diagnosis of MTL epilepsy) are less likely since the epilepsy syndrome itself does not account for a sudden loss of control when drug levels are adequate. 1. Non-adherence is the most common cause of breakthrough seizures in controlled epilepsy. 2. Always check serum AED levels when compliance is in question. 3. Educating patients about consistent medication intake is key. Recent guidelines and clinical studies (including ILAE recommendations) reinforce that non-adherence is a major contributor to breakthrough seizures. Efforts to improve compliance are supported by evidence correlating strict adherence with improved seizure control.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario boy 3 years old with auditory agnosia and delay in language. EEG shows ESES. WHAT IS THE SYNDROME?",
    "option_a": "Landau-Kleffner syndrome",
    "option_b": "Rolandic",
    "option_c": "West",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Landau-Kleffner syndrome is an epileptic encephalopathy characterized by acquired aphasia and abnormal auditory processing (auditory agnosia) in children, associated with abnormal EEG findings like electrical status epilepticus during sleep (ESES). The syndrome is believed to result from aberrant epileptic activity in language-related areas of the brain. During sleep, continuous spike\u2010wave discharges interfere with normal language development and processing, leading to regression and auditory deficits. Clinically, children often present after a period of normal language acquisition with a marked regression in language skills. Auditory agnosia \u2013 the inability to recognize or differentiate sounds \u2013 is a hallmark feature. The EEG pattern of ESES supports this diagnosis. The differential diagnosis includes benign childhood epilepsy with centrotemporal spikes (Rolandic epilepsy), which typically lacks the acquired aphasia and severe language regression, and West syndrome, which presents in infancy with spasms and a hypsarrhythmia pattern on EEG. Detailed EEG evaluation and clinical history help distinguish these entities. Management commonly involves aggressive treatment of the epileptiform activity with high-dose corticosteroids and/or appropriate antiepileptic drugs (e.g., benzodiazepines, valproate). Early intervention is critical to improve language outcomes. In the context of pregnancy or lactation (if applicable in older patients or women with a history), treatment choices should prioritize drugs with established safety profiles and minimize exposure during critical periods. Option A (Landau-Kleffner syndrome) is correct because the clinical features of acquired auditory agnosia, language regression, and an EEG showing ESES are typical for this syndrome. Other options like Rolandic epilepsy or West syndrome do not match the age and core clinical presentations. 1. ESES on EEG is a key diagnostic clue in Landau-Kleffner syndrome. 2. Auditory agnosia is a distinguishing feature of this condition. 3. Early treatment is essential to reduce long-term language deficits. Recent research underscores aggressive early treatment with steroids and modern AEDs to reverse or mitigate language deficits and improve long-term outcomes in Landau-Kleffner syndrome. Updated consensus guidelines emphasize early diagnosis using EEG and prompt intervention.",
    "exam_year": "2022",
    "exam_type": "Part II",
    "image_url": "page_5.png"
  },
  {
    "question": "baby 18 month had 1 febrile seizure what chance to developed epilepsy in future?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Febrile seizures are common in young children and are mostly benign. They are divided into simple forms (generalized, brief, and single episodes) and complex forms. The risk of developing epilepsy later in life following a simple febrile seizure is only slightly higher than in the general population. A simple febrile seizure likely results from immature neuronal networks reacting to fever-induced metabolic changes, without underlying brain pathology. The transient neuronal hyperexcitability does not typically result in chronic epilepsy, although inherent susceptibilities may marginally elevate the risk. In an 18-month-old with a single febrile seizure that fits the criteria for a simple febrile seizure, the future risk of epilepsy is generally quoted as being around 2\u20135%. Multiple, prolonged, or focal features (i.e. complex febrile seizures) would be associated with a higher risk. Since the scenario describes a single episode, the lower risk estimate applies. Differential diagnoses include complex febrile seizures and other seizure etiologies such as central nervous system infections. Usually, normal developmental history and a simple seizure pattern guide the diagnosis. No extensive testing is needed if the clinical picture fits a simple febrile seizure. Management of simple febrile seizures is supportive. First-line approaches include parental reassurance and fever control measures. Intermittent anti-seizure medications (like benzodiazepines) may be reserved for preventing recurrence in children with recurrent or prolonged episodes. In the context of pregnancy or lactation, chronic antiepileptic therapy is not indicated for simple febrile seizures, and management remains supportive with safe antipyretics. Option 1 (3%) is more representative of the risk reported in contemporary studies (approximately 2\u20135%) for a single simple febrile seizure. Option 2 (10%) overestimates the risk and is more typical of scenarios that include complex features or additional risk factors. Options 3 (30%) and 4 (60%) are clearly excessive and unsupported by evidence. 1. The risk of subsequent epilepsy after a single simple febrile seizure is only slightly higher than the baseline risk in the general population. 2. Distinguish between simple and complex febrile seizures to better estimate future epilepsy risk. 3. Parental education and reassurance are paramount in the management of febrile seizures. Recent epidemiological studies and practice guidelines (such as those from the American Academy of Neurology) consistently report that the risk of epilepsy after a simple febrile seizure is about 2\u20135%. This supports using a lower risk estimate (around 3%) rather than the 10% figure, which is more applicable when additional risk factors or complex febrile seizures are present.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "long senario that the mother take her 2 months of age with seizure and history of the same seizure in his older brother and the seizure resolved at age of 8th months of age. What is the gene???",
    "option_a": "",
    "option_b": "",
    "option_c": "(KCNQ2) is correct. SCN1A (Option A) is associated with more severe epilepsy syndromes (e.g., Dravet syndrome), and SCN4A (Option B) is linked to non",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Benign familial neonatal epilepsy (BFNE) typically presents early in life with seizures that resolve within the first months. A positive family history and a transient neonatal seizure presentation are classical features, making genetic testing an important diagnostic tool. Mutations in the KCNQ2 gene disrupt the function of a voltage\u2010gated potassium channel responsible for the M-current, which contributes to stabilizing the neuronal resting potential. This leads to transient neonatal hyperexcitability and seizures that usually resolve by 8 months of age. In the presented case, a neonate with seizures starting at 2 months of age, with resolution by 8 months and a positive family history, strongly supports BFNE. The recurrence in an older sibling further emphasizes the hereditary nature of the condition. Differentiation is needed from other neonatal epilepsies. For example, SCN1A mutations are associated with more severe epileptic syndromes like Dravet syndrome, and SCN4A mutations relate to muscle channelopathies rather than epilepsy. Genetic testing targeting KCNQ2 confirms the diagnosis. Management is largely supportive since the seizures are self-limiting. Acute episodes may be managed with short-term AEDs, but long-term therapy is typically unnecessary. In the context of pregnancy or lactation in a woman with a history of BFNE, careful consideration of AED safety profiles is important if she requires therapy, though most patients do not require chronic treatment. Option C (KCNQ2) is correct. SCN1A (Option A) is associated with more severe epilepsy syndromes (e.g., Dravet syndrome), and SCN4A (Option B) is linked to non-epileptic neuromuscular conditions. 1. BFNE presents in the neonatal period and resolves by infancy. 2. KCNQ2 mutations are the most common cause of BFNE. 3. A positive family history is a key diagnostic indicator. Current genetic studies and updated expert consensus confirm that KCNQ2 mutations are the predominant cause of BFNE. This highlights the clinical importance of genetic testing to ensure accurate diagnosis and counseling.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Effect of hyperventilation on EEG",
    "option_a": "Frontal theta/delta slowing",
    "option_b": "Generalized delta slowing",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Hyperventilation is used as an activation procedure during EEG recording. It causes physiologic changes that produce slowing in the EEG. In normal individuals and in those with certain forms of epilepsy (especially absence epilepsy), hyperventilation can accentuate abnormal cortical rhythms. By hyperventilating, a reduction in arterial CO2 (hypocapnia) occurs, which leads to cerebral vasoconstriction. This in turn reduces cerebral blood flow and alters neuronal excitability, especially in the frontal regions, resulting in slowing (typically theta or delta range) on the EEG. The phenomenon is sometimes seen as frontal intermittent rhythmic delta activity (FIRDA). In many patients, hyperventilation during an EEG may trigger or unveil epileptiform discharges or cause a transient slowing of background activity. In children, for example, hyperventilation is a classic method to provoke absence seizures, which typically present with a 3 Hz spike\u2010and\u2010wave discharge pattern. In other cases, the slowing (often seen in frontal regions) is a normal, transient response to hypocapnia. During an EEG, hyperventilation is routinely used as an activation maneuver. Differential considerations include distinguishing normal physiologic slowing versus pathological epileptiform activity. Other differential diagnoses include drowsiness-related slowing and postictal slowing. Clinical correlation (history of seizures, age, and other findings) helps differentiate these scenarios. Hyperventilation during EEG is a diagnostic tool rather than a treatment modality. No specific treatment is indicated for the slowing observed during the test. In patients with confirmed epilepsy, management would follow current epilepsy guidelines which include first-line anti-epileptic drugs, with special considerations for women who are pregnant or lactating (such as choosing agents with lower teratogenic risk and close monitoring of drug levels). Option A (Frontal theta/delta slowing) correctly identifies the type of EEG change typically seen during hyperventilation. Option B (Generalized delta slowing) may imply a more diffuse effect than is typically observed; the slowing is more accentuated in the frontal regions (FIRDA), making Option A a more accurate description. 1. Hyperventilation reduces CO2 leading to cerebral vasoconstriction and subsequent EEG slowing, particularly in the frontal areas. 2. It is an important activation procedure in EEG, especially for provoking absence seizures in children. 3. FIRDA is a classical pattern seen with hyperventilation. Recent studies continue to support the utility of hyperventilation as an activation technique in EEG. The association between hypocapnia and frontal EEG slowing has been well documented, and its use in clinical settings remains standard practice.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient went for dental procedure had brief LOC what favor seizure, not syncope",
    "option_a": "(Cyanosis) is correct because cyanosis during a brief LOC episode suggests a seizure due to hypoxia from impaired ventilation. The other options are either not provided or represent findings that do not specifically differentiate between seizure and syncope.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "Differentiating between seizure and syncope during a brief loss of consciousness (LOC) is critical. Certain clinical signs, like cyanosis, can help distinguish between the two. In seizures, impaired ventilation often leads to hypoxia and resultant cyanosis. During a generalized tonic-clonic seizure, there is often a period of apnea and impaired airway protection. This hypoventilation leads to a drop in blood oxygen saturation, causing cyanosis. In contrast, syncope, which results from transient cerebral hypoperfusion, usually resolves quickly without significant respiratory compromise. In the scenario where a patient experiences brief LOC after a dental procedure, the presence of cyanosis supports the diagnosis of a seizure rather than a vasovagal syncope. Other features favoring seizures include tonic-clonic movements, tongue biting, and postictal confusion. The evaluation should include a detailed history (including witness accounts), physical examination, and an EEG if a seizure is suspected. Differential diagnoses include vasovagal syncope (which typically lacks cyanosis and postictal confusion), cardiac arrhythmias, and hypoglycemia-induced events. Once a seizure is diagnosed, treatment involves initiating or optimizing anti-epileptic drugs (AEDs) based on seizure type and patient characteristics. In pregnancy, careful selection of AEDs that minimize teratogenicity (e.g., levetiracetam) is crucial, and during lactation, drug levels and potential infant exposure need to be monitored closely. Option A (Cyanosis) is correct because cyanosis during a brief LOC episode suggests a seizure due to hypoxia from impaired ventilation. The other options are either not provided or represent findings that do not specifically differentiate between seizure and syncope. 1. Cyanosis during a loss of consciousness episode suggests impaired ventilation, favoring a seizure over syncope. 2. Syncope typically resolves quickly without significant respiratory compromise. 3. Detailed witness history and physical exam help distinguish seizures from other causes of LOC. Recent literature and guidelines emphasize the significance of clinical signs, such as cyanosis, in differentiating seizures from syncope. Studies have consistently found that features like prolonged postictal confusion and cyanosis are more common in epileptic events than in syncope.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has seizure recurrence on topiramate 200mg and CBZ 400mg bid came with breakthrough seizure what is the cause, EEG pic showed spikes in temporal lobe, and MRI showed MTS, no more details",
    "option_a": "(Drug interactions) is less likely without evidence of new interfering medications and given the clear structural abnormality. Option C (Interictal spikes) are an EEG marker but not the cause of seizures. Option D (Poor compliance) is not indicated by the provided history. Option B (MTS) is the correct cause of the breakthrough seizures, making it the correct answer.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial temporal sclerosis (MTS) is recognized as one of the most common causes of refractory temporal lobe epilepsy. The presence of structural abnormalities within the mesial temporal lobe can lead to recurrent seizures despite therapeutic drug levels. MTS is characterized by neuronal loss and gliosis in the hippocampal formation. This scarring disrupts normal neuronal circuitry and creates an epileptogenic focus, leading to abnormal discharges seen on EEG. MRI findings typically reveal atrophy and increased signal intensity in the mesial temporal region consistent with sclerosis. In the described case, the patient on topiramate and carbamazepine experiencing breakthrough seizures, along with EEG findings of temporal spikes and MRI evidence of MTS, strongly indicates that the structural lesion (MTS) is the primary cause of the recurrent seizures. This is more definitive than attributing the seizures to interictal spikes, drug interactions, or poor compliance. Diagnosis of refractory temporal lobe epilepsy involves correlating clinical history with EEG findings and neuroimaging. The differential diagnosis to consider includes drug interactions (which may lower serum levels of AEDs), non-adherence, and other structural lesions. In this case, the MRI evidence of MTS confirms the diagnosis. First-line management involves optimization of AED therapy, but in cases of confirmed MTS with breakthrough seizures, surgical evaluation (such as anterior temporal lobectomy) is recommended. For patients of childbearing potential, especially if pregnant or lactating, AED selection must balance seizure control with teratogenic risk. Multidisciplinary management, including neurology and obstetrics, is essential. Option A (Drug interactions) is less likely without evidence of new interfering medications and given the clear structural abnormality. Option C (Interictal spikes) are an EEG marker but not the cause of seizures. Option D (Poor compliance) is not indicated by the provided history. Option B (MTS) is the correct cause of the breakthrough seizures, making it the correct answer. 1. MTS is a common cause of refractory temporal lobe epilepsy and often necessitates a surgical work-up. 2. Structural lesions like MTS are best confirmed with MRI, which guides treatment decisions. 3. Always consider both clinical and imaging findings in evaluating breakthrough seizures. Recent guidelines and studies emphasize early consideration of surgical therapy in patients with temporal lobe epilepsy due to MTS that is refractory to medical management. Therapeutic drug monitoring and careful assessment of compliance remain important, but the presence of a clear structural abnormality often drives the need for surgical intervention.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "long senario 2 years baby with development delay and tonic clonic ssizure and drop seizure of LGs what you will find In EEG?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Epilepsy",
    "explanation": "Lennox-Gastaut Syndrome (LGS) is a severe childhood epileptic encephalopathy with multiple seizure types, cognitive impairment, and a characteristic EEG pattern. The syndrome typically presents in young children with diverse seizure semiologies including tonic, atonic (drop attacks), and atypical absence seizures. LGS is associated with widespread cortical dysfunction and abnormal synchronization of neuronal firing. The hallmark EEG pattern in LGS is the slow spike-and-wave complex, usually seen at a frequency of approximately 1.5-2.5 Hz. This is distinct from the 3 Hz spike-and-wave pattern seen in typical childhood absence epilepsy. A 2-year-old with developmental delay and a mix of tonic-clonic and drop seizures fits the classic clinical presentation of LGS. The typical EEG finding, slow (<3 Hz) spike-and-wave discharges, aids in differentiating LGS from other pediatric epilepsies. Diagnosis is based on a combination of clinical presentation, developmental history, and EEG findings. Differential diagnoses include childhood absence epilepsy (characterized by a 3 Hz spike-and-wave pattern) and other epileptic encephalopathies. Neuroimaging is used to rule out structural causes, but the diagnosis of LGS is primarily clinical and electrophysiological. Management is challenging and typically involves a combination of multiple anti-epileptic drugs (such as valproate, lamotrigine, and topiramate), dietary therapies (e.g., ketogenic diet), and sometimes surgical interventions (e.g., corpus callosotomy) when seizures are refractory. In pregnant or lactating women, AEDs must be chosen carefully to minimize teratogenic effects, and folic acid supplementation is advised. Option 1 suggests a 3 Hz spike-and-wave pattern, which is characteristic of childhood absence epilepsy rather than LGS. Option 2 (spike less than 2 seconds) is non-specific and not central to LGS diagnosis. Option 3 (spike 4-6 seconds) is physiologically implausible for epileptiform discharges. Therefore, none of the provided options accurately describe the classical slow spike-and-wave EEG pattern (approximately 1.5-2.5 Hz) seen in LGS. 1. Always remember that the classic EEG pattern in LGS is slow spike-and-wave complexes at around 1.5-2.5 Hz, not the 3 Hz pattern seen in typical absence seizures. 2. LGS is a severe and difficult-to-treat epilepsy syndrome with a high risk of cognitive impairment. 3. Early diagnosis and multi-modal management are critical for optimizing outcomes in children with LGS. Current research underlines the importance of early intervention and a multimodal treatment approach in LGS. Recent guidelines stress the need for individualized therapy, including the early use of dietary and surgical options in drug-resistant cases, as well as careful monitoring of AED levels during pregnancy to minimize fetal exposure to teratogenic drugs.",
    "exam_year": "2022",
    "exam_type": "Part II",
    "image_url": "page_4.png"
  },
  {
    "question": "Clear scenario pt with epileptic spasms and EEG showing hypsarrhythmia, whats the dx (they didn\u2019t say the EEG findings, literally what is the diagnosis)",
    "option_a": "('Hypsarrhythmia') is incorrect because it describes the EEG pattern, not the clinical diagnosis. Option B ('None') is considered correct, as the true diagnosis in the scenario is infantile spasms (West syndrome) and not just the EEG finding. Thus, the marked answer A is incorrect.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Infantile spasms, also known as West syndrome, is a distinct epileptic encephalopathy of infancy characterized clinically by epileptic spasms and typically accompanied by a chaotic EEG pattern called hypsarrhythmia. It is essential to distinguish between an EEG pattern (hypsarrhythmia) and the clinical syndrome (infantile spasms/West syndrome). Infantile spasms can result from diverse etiologies such as structural brain abnormalities, genetic disorders, or metabolic causes. The underlying mechanism involves disordered neuronal network development, leading to abnormal cortical excitability and the typical chaotic, high-amplitude, disorganized EEG pattern (hypsarrhythmia). This abnormal electrographic activity is a hallmark rather than the diagnosis itself. Clinically, infants present with clusters of brief, symmetric spasms usually occurring in the first year of life, often with developmental regression. The presence of hypsarrhythmia on EEG reinforces the diagnosis but cannot stand alone without the clinical picture of spasms. Diagnosis is based on the clinical history of spasms plus EEG findings. A thorough work-up might include neuroimaging (MRI) to identify structural causes, metabolic and genetic testing when indicated, and sometimes evaluation for underlying tuberous sclerosis. Differential diagnoses include Dravet syndrome or other early-onset epileptic encephalopathies, but these usually have distinguishing seizure types and EEG features. According to the latest guidelines, first-line treatments include adrenocorticotropic hormone (ACTH) or high-dose oral corticosteroids and vigabatrin, especially if tuberous sclerosis is present. Second-line options may include other antiepileptic drugs. Although pregnancy considerations are not directly applicable to infants, in scenarios involving lactating mothers (e.g., when drugs are used for maternal epilepsy), clinicians must weigh the risk of drug passage in breast milk against seizure control. Option A ('Hypsarrhythmia') is incorrect because it describes the EEG pattern, not the clinical diagnosis. Option B ('None') is considered correct, as the true diagnosis in the scenario is infantile spasms (West syndrome) and not just the EEG finding. Thus, the marked answer A is incorrect. 1. Always correlate EEG findings with clinical symptomatology. 2. Early recognition and treatment of infantile spasms can improve long-term neurodevelopmental outcomes. 3. West syndrome is a diagnosis based on a classic clinical triad, not solely on EEG abnormalities. Recent clinical studies support the use of ACTH and vigabatrin as first-line treatments in infantile spasms, with ongoing research to refine dosing regimens and treatment duration to optimize neurodevelopmental outcomes.",
    "exam_year": "2022",
    "exam_type": "Part II",
    "image_url": "page_26.png"
  },
  {
    "question": "Child with perisylphian atrophy and unilateral weakness, had initially focal seizure then focal status what is the ab",
    "option_a": "(GluR3) is correct, as the GluR3 antibody is implicated in this scenario. Other options typically pertain to different antibodies or etiologies that do not match the clinical and imaging findings described.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Autoimmune epilepsy in children can present with focal seizures and progressive unilateral neurological deficits. The presence of focal seizures, especially when accompanied by unilateral weakness and regional atrophy on imaging, raises suspicion for an autoimmune etiology. GluR3 antibodies target a subunit of the AMPA receptor, leading to an autoimmune attack that results in focal cortical inflammation and subsequent atrophy, especially in regions such as the perisylvian cortex. This autoimmune process causes neuronal injury and manifests as focal seizures that can progress to focal status epilepticus. The clinical presentation of initial focal seizures progressing to focal status epilepticus, coupled with imaging evidence of perisylvian atrophy and unilateral weakness, is characteristic of an autoimmune-mediated process. GluR3 autoimmunity has been implicated in conditions like Rasmussen\u2019s encephalitis, which present similarly. Diagnosis involves correlating clinical signs with neuroimaging (MRI showing focal atrophy) and confirming the presence of GluR3 antibodies via serum or cerebrospinal fluid analysis. The differential diagnosis includes other autoimmune encephalitides such as anti-NMDA receptor encephalitis or LGI1-related encephalopathy, but these often have different clinical profiles and broader presentations, including psychiatric symptoms or faciobrachial dystonic seizures. First-line treatment includes immunomodulatory therapies such as corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis combined with antiepileptic medications to control seizures. In refractory cases, surgical options such as hemispherotomy may be considered. In pregnant or lactating women, immunotherapy and AED selection should be done cautiously, tailoring the regimen to minimize fetal and neonatal risk while controlling the autoimmune process. Option A (GluR3) is correct, as the GluR3 antibody is implicated in this scenario. Other options typically pertain to different antibodies or etiologies that do not match the clinical and imaging findings described. 1. Focal neurological deficits with regional cortical atrophy in children should prompt consideration of autoimmune etiologies. 2. GluR3 antibodies have been historically associated with autoimmune encephalitides like Rasmussen\u2019s encephalitis. 3. Early immunotherapy is crucial to halt progression in autoimmune epilepsy. Current research emphasizes early detection of autoimmune markers and immediate initiation of immunotherapy to reduce neurological damage. Although the role of GluR3 antibodies is still under investigation, multiple studies support their association with focal, refractory epilepsies in children.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario infant with myolconus started focaly and become progressive what to expect on EEG",
    "option_a": "(Burst suppression) is the correct EEG finding expected in a progressive PME with severe encephalopathic changes. The marked answer D is incorrect because it does not match this advanced EEG pattern.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Progressive myoclonus epilepsies (PME) represent a heterogeneous group of disorders characterized by myoclonic seizures that can begin focally and become progressively generalized. EEG patterns are critical in determining the severity and stage of the disease. In advanced stages of PME, severe cortical dysfunction leads to an EEG pattern termed burst suppression \u2013 alternating periods of high-voltage bursts followed by near-flat suppression. This indicates a profound impairment of neuronal activity and a more advanced encephalopathic state. As PME progresses, patients may initially exhibit focal myoclonic jerks that evolve into continuous or near-continuous seizure activity. The appearance of burst suppression on EEG correlates with worsening neuronal function and a poor prognosis, reflecting the transition to a more encephalopathic state. Diagnosis is based on clinical features of progressive myoclonus, supported by EEG findings. The differential diagnosis includes conditions such as juvenile myoclonic epilepsy (which exhibits generalized spike-and-wave discharges) and other causes of myoclonus like metabolic encephalopathies; however, burst suppression is indicative specifically of advanced cortical failure in PME. Management focuses on symptomatic treatment with antiepileptic drugs (AEDs) such as valproate, levetiracetam, and clonazepam. In advanced stages, supportive care becomes paramount due to the refractory nature of the seizures. For women of childbearing potential, particularly those who are pregnant or lactating, preference is given to AEDs with lower teratogenic risks (for example, levetiracetam over valproate) while balancing seizure control. Option A (Burst suppression) is the correct EEG finding expected in a progressive PME with severe encephalopathic changes. The marked answer D is incorrect because it does not match this advanced EEG pattern. 1. Burst suppression on EEG is a sign of severe cortical failure and advanced encephalopathy. 2. PME often evolves from focal myoclonus to a generalized, devastating clinical picture. 3. EEG findings provide critical prognostic information in progressive epileptic disorders. Recent studies continue to highlight the prognostic significance of burst suppression in PME. Research is ongoing in understanding the genetic and molecular mechanisms underlying PME, with clinical trials exploring newer AEDs and gene therapies to potentially modify disease course.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came to the clinic with facial and arm twitches, and pronator drift, occasionally stop not mention of LOC, to me look like EPC ask about dx",
    "option_a": "Subtle status epilepticus",
    "option_b": "Status epilepticus",
    "option_c": "EPC",
    "option_d": "Seizure cluster",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "Epilepsia partialis continua (EPC) is a unique form of focal status epilepticus characterized by continuous or near-continuous focal motor seizures, typically without impairment of consciousness. It specifically involves a restricted region of the motor cortex. EPC results from localized cortical hyperexcitability often due to structural lesions (such as cortical infarcts, tumors, or inflammatory processes) or metabolic abnormalities. The persistent electrical activity in a focal motor region leads to rhythmic twitching of a body part. Patients with EPC present with continuous or recurring focal motor seizures, as illustrated by persistent facial and arm twitches and signs such as pronator drift. The absence of loss of consciousness and the focal nature of the symptoms help differentiate EPC from generalized seizure activity. Diagnosis is primarily clinical, supported by EEG that shows focal epileptiform discharges in the corresponding cortical area. Neuroimaging, typically MRI, is used to identify any underlying structural lesion. Differential diagnoses include subtle status epilepticus (which may have less overt clinical signs), generalized status epilepticus, and seizure clusters, but these typically involve different clinical presentations and EEG patterns. First-line management includes the use of antiepileptic drugs such as benzodiazepines, levetiracetam, or phenytoin aimed at controlling focal seizure activity. In resistant cases, additional therapies such as immunotherapy (if an inflammatory lesion is suspected) or even surgical evaluation may be warranted. In pregnant or lactating women, drug selection is critical; agents like levetiracetam are preferred due to a safer teratogenic profile relative to others. Option C (EPC) is correct because the clinical presentation \u2014 focal, continuous twitching of the face and arm with preserved awareness \u2014 is characteristic of epilepsia partialis continua. Options such as subtle status epilepticus, generalized status epilepticus, or seizure clusters do not appropriately describe this localized continuous phenomenon. 1. EPC is a form of focal status epilepticus that presents with continuous, localized motor activity. 2. The preservation of consciousness is a key distinguishing feature of EPC. 3. Focused neurological signs, such as pronator drift, help confirm localization of the ictal focus. Recent guidelines emphasize the rapid recognition and management of EPC due to its potential for permanent neurological damage. Current research is focused on improving diagnostic accuracy with advanced imaging and refining AED protocols to minimize adverse effects, particularly in sensitive populations such as pregnant or lactating women.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario but came to ER what is the tx",
    "option_a": "IV diazepam",
    "option_b": "IV phenytoin",
    "option_c": "IV VPA",
    "option_d": "IV levetiracetam",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In the acute management of seizures, particularly when a patient presents to the emergency room in a state of ongoing seizure activity (or status epilepticus), the primary goal is rapid seizure termination. Benzodiazepines are the first\u2010line agents because of their rapid onset of action and their ability to enhance GABAergic inhibition. Status epilepticus represents a prolonged period of uncontrolled electrical activity in the brain. Continued seizure activity leads to pathologic changes at the receptor level, including a reduced sensitivity to GABA due to receptor internalization. Benzodiazepines, such as diazepam, work by binding to the GABA-A receptor complex, increasing the frequency of chloride channel opening, hyperpolarizing neurons, and thereby helping to abort the seizure. Patients in status epilepticus or with ongoing seizure activity may present with altered mental status, convulsions, and potential respiratory compromise. Immediate treatment is essential to prevent neuronal injury and systemic complications. In the emergency room, the emphasis is on rapid seizure control while maintaining airway, breathing, and circulation. While the clinical picture is paramount, the differential diagnosis in a patient with altered mental status may include syncope, metabolic disturbances, intoxication, or stroke. Laboratory tests, neuroimaging, and an EEG (if indicated later) help to rule out mimics. In this acute setting, rapid clinical assessment directs immediate treatment. Tiered management of status epilepticus typically begins with a fast-acting benzodiazepine. First-line: IV benzodiazepines (preferably IV lorazepam if available; IV diazepam is an acceptable alternative, especially if lorazepam isn\u2019t available). Second-line: If seizures continue, options include IV phenytoin/fosphenytoin, IV valproate, or IV levetiracetam. Pregnancy and lactation considerations: While benzodiazepines cross the placenta, in emergencies the maternal benefit outweighs fetal risks; however, care is needed, and lorazepam or diazepam should be used at the lowest effective dose. Option A (IV diazepam) is the correct first-line treatment in an emergency setting for stopping acute seizure activity. Options B (IV phenytoin), C (IV valproate), and D (IV levetiracetam) are considered second-line or alternative agents if the initial benzodiazepine fails to terminate the seizure. 1. The earlier a benzodiazepine is administered in status epilepticus, the better the outcome due to increased drug sensitivity before receptor changes occur. 2. Although IV lorazepam is often preferred, IV diazepam is an acceptable alternative in many emergency protocols. 3. Rapid stabilization (ABCs) is critical even as medications are being administered. Recent guidelines from bodies such as the Neurocritical Care Society and the American Epilepsy Society continue to endorse IV benzodiazepines as the first-line therapy in status epilepticus, with multiple studies confirming that early intervention reduces morbidity and mortality.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "AED that worsen myoclonus",
    "option_a": "Phenobarbital",
    "option_b": "Topiramate",
    "option_c": "Levetiraceram",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Epilepsy",
    "explanation": "In the acute management of seizures, particularly when a patient presents to the emergency room in a state of ongoing seizure activity (or status epilepticus), the primary goal is rapid seizure termination. Benzodiazepines are the first\u2010line agents because of their rapid onset of action and their ability to enhance GABAergic inhibition. Status epilepticus represents a prolonged period of uncontrolled electrical activity in the brain. Continued seizure activity leads to pathologic changes at the receptor level, including a reduced sensitivity to GABA due to receptor internalization. Benzodiazepines, such as diazepam, work by binding to the GABA-A receptor complex, increasing the frequency of chloride channel opening, hyperpolarizing neurons, and thereby helping to abort the seizure. Patients in status epilepticus or with ongoing seizure activity may present with altered mental status, convulsions, and potential respiratory compromise. Immediate treatment is essential to prevent neuronal injury and systemic complications. In the emergency room, the emphasis is on rapid seizure control while maintaining airway, breathing, and circulation. While the clinical picture is paramount, the differential diagnosis in a patient with altered mental status may include syncope, metabolic disturbances, intoxication, or stroke. Laboratory tests, neuroimaging, and an EEG (if indicated later) help to rule out mimics. In this acute setting, rapid clinical assessment directs immediate treatment. Tiered management of status epilepticus typically begins with a fast-acting benzodiazepine. First-line: IV benzodiazepines (preferably IV lorazepam if available; IV diazepam is an acceptable alternative, especially if lorazepam isn\u2019t available). Second-line: If seizures continue, options include IV phenytoin/fosphenytoin, IV valproate, or IV levetiracetam. Pregnancy and lactation considerations: While benzodiazepines cross the placenta, in emergencies the maternal benefit outweighs fetal risks; however, care is needed, and lorazepam or diazepam should be used at the lowest effective dose. Option A (IV diazepam) is the correct first-line treatment in an emergency setting for stopping acute seizure activity. Options B (IV phenytoin), C (IV valproate), and D (IV levetiracetam) are considered second-line or alternative agents if the initial benzodiazepine fails to terminate the seizure. 1. The earlier a benzodiazepine is administered in status epilepticus, the better the outcome due to increased drug sensitivity before receptor changes occur. 2. Although IV lorazepam is often preferred, IV diazepam is an acceptable alternative in many emergency protocols. 3. Rapid stabilization (ABCs) is critical even as medications are being administered. Recent guidelines from bodies such as the Neurocritical Care Society and the American Epilepsy Society continue to endorse IV benzodiazepines as the first-line therapy in status epilepticus, with multiple studies confirming that early intervention reduces morbidity and mortality.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Pt with features suggestive of abcen and EEG showing 3Hz SW which of the following medication might worsen the seizure",
    "option_a": "Oxcarbezapine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "In the acute management of seizures, particularly when a patient presents to the emergency room in a state of ongoing seizure activity (or status epilepticus), the primary goal is rapid seizure termination. Benzodiazepines are the first\u2010line agents because of their rapid onset of action and their ability to enhance GABAergic inhibition. Status epilepticus represents a prolonged period of uncontrolled electrical activity in the brain. Continued seizure activity leads to pathologic changes at the receptor level, including a reduced sensitivity to GABA due to receptor internalization. Benzodiazepines, such as diazepam, work by binding to the GABA-A receptor complex, increasing the frequency of chloride channel opening, hyperpolarizing neurons, and thereby helping to abort the seizure. Patients in status epilepticus or with ongoing seizure activity may present with altered mental status, convulsions, and potential respiratory compromise. Immediate treatment is essential to prevent neuronal injury and systemic complications. In the emergency room, the emphasis is on rapid seizure control while maintaining airway, breathing, and circulation. While the clinical picture is paramount, the differential diagnosis in a patient with altered mental status may include syncope, metabolic disturbances, intoxication, or stroke. Laboratory tests, neuroimaging, and an EEG (if indicated later) help to rule out mimics. In this acute setting, rapid clinical assessment directs immediate treatment. Tiered management of status epilepticus typically begins with a fast-acting benzodiazepine. First-line: IV benzodiazepines (preferably IV lorazepam if available; IV diazepam is an acceptable alternative, especially if lorazepam isn\u2019t available). Second-line: If seizures continue, options include IV phenytoin/fosphenytoin, IV valproate, or IV levetiracetam. Pregnancy and lactation considerations: While benzodiazepines cross the placenta, in emergencies the maternal benefit outweighs fetal risks; however, care is needed, and lorazepam or diazepam should be used at the lowest effective dose. Option A (IV diazepam) is the correct first-line treatment in an emergency setting for stopping acute seizure activity. Options B (IV phenytoin), C (IV valproate), and D (IV levetiracetam) are considered second-line or alternative agents if the initial benzodiazepine fails to terminate the seizure. 1. The earlier a benzodiazepine is administered in status epilepticus, the better the outcome due to increased drug sensitivity before receptor changes occur. 2. Although IV lorazepam is often preferred, IV diazepam is an acceptable alternative in many emergency protocols. 3. Rapid stabilization (ABCs) is critical even as medications are being administered. Recent guidelines from bodies such as the Neurocritical Care Society and the American Epilepsy Society continue to endorse IV benzodiazepines as the first-line therapy in status epilepticus, with multiple studies confirming that early intervention reduces morbidity and mortality.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "20 YO male with generalized tonic clonic seizure on lamotrogine 200mg bid and had breakthrough seizure what is the next appropriate medication",
    "option_a": "Valproate",
    "option_b": "Levetiracetam",
    "option_c": "Topiramate",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "In the acute management of seizures, particularly when a patient presents to the emergency room in a state of ongoing seizure activity (or status epilepticus), the primary goal is rapid seizure termination. Benzodiazepines are the first\u2010line agents because of their rapid onset of action and their ability to enhance GABAergic inhibition. Status epilepticus represents a prolonged period of uncontrolled electrical activity in the brain. Continued seizure activity leads to pathologic changes at the receptor level, including a reduced sensitivity to GABA due to receptor internalization. Benzodiazepines, such as diazepam, work by binding to the GABA-A receptor complex, increasing the frequency of chloride channel opening, hyperpolarizing neurons, and thereby helping to abort the seizure. Patients in status epilepticus or with ongoing seizure activity may present with altered mental status, convulsions, and potential respiratory compromise. Immediate treatment is essential to prevent neuronal injury and systemic complications. In the emergency room, the emphasis is on rapid seizure control while maintaining airway, breathing, and circulation. While the clinical picture is paramount, the differential diagnosis in a patient with altered mental status may include syncope, metabolic disturbances, intoxication, or stroke. Laboratory tests, neuroimaging, and an EEG (if indicated later) help to rule out mimics. In this acute setting, rapid clinical assessment directs immediate treatment. Tiered management of status epilepticus typically begins with a fast-acting benzodiazepine. First-line: IV benzodiazepines (preferably IV lorazepam if available; IV diazepam is an acceptable alternative, especially if lorazepam isn\u2019t available). Second-line: If seizures continue, options include IV phenytoin/fosphenytoin, IV valproate, or IV levetiracetam. Pregnancy and lactation considerations: While benzodiazepines cross the placenta, in emergencies the maternal benefit outweighs fetal risks; however, care is needed, and lorazepam or diazepam should be used at the lowest effective dose. Option A (IV diazepam) is the correct first-line treatment in an emergency setting for stopping acute seizure activity. Options B (IV phenytoin), C (IV valproate), and D (IV levetiracetam) are considered second-line or alternative agents if the initial benzodiazepine fails to terminate the seizure. 1. The earlier a benzodiazepine is administered in status epilepticus, the better the outcome due to increased drug sensitivity before receptor changes occur. 2. Although IV lorazepam is often preferred, IV diazepam is an acceptable alternative in many emergency protocols. 3. Rapid stabilization (ABCs) is critical even as medications are being administered. Recent guidelines from bodies such as the Neurocritical Care Society and the American Epilepsy Society continue to endorse IV benzodiazepines as the first-line therapy in status epilepticus, with multiple studies confirming that early intervention reduces morbidity and mortality.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]